12月16日，科伦博泰生物-B(06990)盘中下跌5.06%，截至09:59，报178.1元/股，成交675.62万元。
四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司，主要以抗体药物偶联物（ADC）的技术平台为基础，致力于解决全球普遍或难以治疗的癌症以及众多患人医疗需求未满足的其他疾病。公司拥有完善的一体化药物开发机制，已建立包含研发、生产、质量控制及商业化等全面功能的一体化能力，并有30多款差异化且具有临床价值的资产管线，其中10余款处于临床阶段。
截至2024年中报，科伦博泰生物-B营业总收入13.83亿元、净利润3.1亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.